Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 11/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552813 | 0.93 | ABCG2 (0.46) | ABCG2TAS2R14ABCB1PDK2AXL | |
| SCHEMBL25787707 | 0.90 | PDK2 (0.43) | ABCG2TAS2R14ABCB1PDK2AXL | |
| SCHEMBL25787244 | 0.84 | ABCG2 (0.46) | ABCG2TAS2R14ABCB1BRAF | |
| SCHEMBL21749269 | 0.84 | ABCG2 (0.46) | ABCG2TAS2R14ABCB1 | |
| SCHEMBL20552969 | 0.83 | ABCG2 (0.43) | ABCG2TAS2R14ABCB1 | |
| SCHEMBL25787257 | 0.83 | DDX3X (0.55) | ABCG2TAS2R14ABCB1 | |
| SCHEMBL21054150 | 0.83 | TEAD1 (0.40) | ABCG2PDK2 | |
| SCHEMBL20552265 | 0.83 | ABCG2 (0.45) | ABCG2TAS2R14ABCB1 | |
| SCHEMBL20552643 | 0.83 | ABCG2 (0.47) | ABCG2TAS2R14ABCB1 | |
| SCHEMBL21749295 | 0.83 | ABCG2 (0.43) | ABCG2TAS2R14ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| CN-111132673-A | Non-fused tricyclic compounds | 维瓦斯治疗公司 | 2020-05-08 | — | — | CN | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | ABCG2 3004/4885TAS2R14 4740/4885ABCB1 1774/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | ABCG2 3004/4885TAS2R14 4740/4885ABCB1 1774/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | ABCG2 2217/4885TAS2R14 3753/4885ABCB1 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.